nutriband inc emerg leader transderm
patch market medic consum applic
recent acquisit lead player therapeut
ad technolog formula expertis expand
fentanyl transderm patch type diabet
market among other offer third parti test
servic compani also partner best
choic inc distribut transderm patch
consum market asia
roll-out defent
reiter buy rate price target nutriband push
roll-out compani anti-deterr fentanyl transderm patch
defent compani still complet recent file
public offer capit current begin process
receiv fda approv defent said recent bridg financ
hope set nutriband complet plan public offer
base upon latest file believ current contempl public
offer provid adequ capit begin process receiv
fda approv assum roll-out defent
state oper limbo octob revenu
slightli project driven entir
contract research develop busi expect
best choic compani asian partner still receiv
govern approv sell nutriband consum product south
korea nutriband recogn revenu sale
consum product continu assum increment
revenu best choic project
loss per share exclud deriv driven
expens slightli better expect frankli materi
way overal longer term nutriband stori
octob bridg financ provid near term stabil end
octob nutriband issu two investor one
year convert promissori note warrant purchas
ntrb share lower price
contempl public stock offer note must repaid
complet equiti offer million
repaid par first day issuanc
par thereaft serv materi stick complet
complet propos latest prospectu current stock
offer financ fda approv defent latest
file decemb file contempl offer
ntrb share similar number warrant
purchas ntrb stock green shoe
common stock warrant underwrit
commiss assum warrant exercis nutriband
receiv gross proce million
allow fda approv defent higher side
start work transderm technolog
push back project roll-out defent given
compani abl begin process obtain fda approv
defent due limit capit project roll-out
longer feasibl therefor push roll-out defent back year
assum closur current contempl public offer
end april given compani file first
prospectu june believ offer actual complet
project roll-out defent remain uncertain
lower ep loss per share ep
reflect pushback defent roll-out new ep
incorpor expect roll-out defent issuanc
ntrb share common stock warrant exercis
reiter buy rate ep project
nutriband continu believ need fentanyl deterr
defent repres simpl easi solut compel cost
effect said frustrat rais necessari capit fda
approv on-going hope recent bridg financ serv
final piec nutriband complet offer begin
process fda approv defent
good sold
cost expens
eric beder certifi view express includ limit price target rate financi estim herein accur reflect person view
secur compani compani mention report
valuat price target ntrb translat ep
risk buy rate price target ntrb includ limit compani materi growth driver defent approv
fda transderm patch market remain highli fragment nutriband compet player materi larger size financi resourc
compani fulli financ plan product rollout compani asian partner best choic approv sell nutriband product key
south korean market nutriband financi statement includ going-concern qualif invest earli stage medic compani entail high level
risk view ntrb suitabl invest conserv investor
rate distribut percentag invest bank disclosur chart inform
